Moderate

Severe asthma — assessment & biologic therapy

T2-high phenotyping · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Severe asthma is uncontrolled or requiring high-dose ICS-LABA (+ a fourth controller) despite confirmed diagnosis, good adherence and technique. Biologics target type-2 (T2) inflammation and reduce exacerbations and oral steroid burden in eligible phenotypes.

Red flags

  • Life-threatening exacerbations despite maximal therapy
  • Rising eosinophils with rash/neuropathy/sinusitis suggesting EGPA
  • OCS-dependence with cushingoid features and adrenal suppression
  • New fever/weight loss suggesting infection or malignancy mimicking asthma

Assessment

Differential diagnosis

  • Difficult-to-control (not truly severe) asthma — poor adherence/technique
  • Inducible laryngeal obstruction / vocal cord dysfunction
  • COPD or asthma-COPD overlap
  • EGPA / eosinophilic lung disease
  • ABPA
  • Cardiac failure or chronic thromboembolic disease mimicking refractory breathlessness

Investigations

  • Confirm diagnosis: spirometry with reversibility, FeNO, peak flow variability
  • Blood eosinophil count (off/lowest OCS) and total IgE plus aeroallergen specific IgE / skin testing
  • FeNO (T2 biomarker)
  • Chest imaging (HRCT if atypical) and consider bronchoscopy if indicated
  • Aspergillus IgE/IgG, ANCA, periostin where available
  • Adherence check (prescription records, FeNO suppression test) and inhaler technique review
  • Comorbidity screen: CRSwNP, GORD, OSA, obesity, anxiety

Management

  • Confirm the diagnosis objectively and exclude mimics before labelling severe asthma
  • Verify adherence (dispensing data, directly observed ICS/FeNO suppression) and correct inhaler technique
  • Optimise treatable traits: nasal polyps, GORD, obesity, smoking, allergen/occupational exposures, psychosocial factors
  • Ensure maximal inhaled therapy — high-dose ICS-LABA, add LAMA, consider trial of macrolide or LTRA per guideline
  • Phenotype as T2-high vs T2-low using eosinophils, FeNO, IgE and allergen sensitisation
  • Refer to a specialist severe-asthma service / MDT for biologic consideration
  • Choose biologic by phenotype: anti-IgE (allergic), anti-IL5/IL5R (eosinophilic), anti-IL4R (broad T2), anti-TSLP (broad, biomarker-agnostic)
  • Record baseline exacerbation rate, OCS dose, ACQ/ACT and FEV1 for response assessment
  • Commence biologic and reassess response at ~4 months (exacerbations, symptoms, OCS, lung function)
  • If responding, taper maintenance oral corticosteroids cautiously with adrenal-axis awareness
  • If no response, reassess diagnosis/adherence and switch biologic class
  • Arrange annual review, bone protection and steroid-sparing monitoring

Drugs & doses

Omalizumab 75-600 mg SC every 2-4 weeks (dose by weight and IgE)
Mepolizumab 100 mg SC every 4 weeks
Benralizumab 30 mg SC every 4 weeks x3 then every 8 weeks
Dupilumab 400 mg then 200 mg SC every 2 weeks (or 600/300 mg if OCS-dependent or with CRSwNP)
Tezepelumab 210 mg SC every 4 weeks
Prednisolone taper individualised while monitoring adrenal axis

Disposition

Specialist severe-asthma MDT clinic. Admit life-threatening exacerbations. Escalate OCS-dependent or EGPA-suspected cases to respiratory/immunology.

Complications & pitfalls

  • Oral corticosteroid toxicity (osteoporosis, diabetes, cataract, adrenal suppression)
  • Unmasking of EGPA on steroid/biologic taper
  • Anaphylaxis to biologic (esp. omalizumab)
  • Persistent airflow limitation / airway remodelling

Exam pearls

  • A FeNO suppression test can distinguish non-adherence from true steroid-refractory disease
  • Blood eosinophils fall on oral steroids — interpret biomarkers in that context
  • Dupilumab can cause transient hypereosinophilia; monitor if baseline count is high
  • Biologic response is judged at ~4 months, not weeks

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.